December 8, 2025BloodOpen Access

Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.

View Full Paper

Ask AI

Bookmark

Authors

TLThomas LundInstitute of Cancer Research ETElena Manuela TeodorescuAalborg University Hospital MSMorten SalomoJohnson & Johnson (United States)

Discussion

Member takes

Implication

Observational study shows prophylactic tocilizumab reduces cytokine release syndrome in relapsed/refractory multiple myeloma, indicating a safer approach.

Key Points

Prophylactic tocilizumab lowers incidence of cytokine release syndrome during step-up dosing of teclistamab, enhancing safety.
Overall response rate was 64% in the prophylactic group vs. 55% without, underscoring efficacy.
Retrospective multicenter study reviewed outcomes from multiple Danish centers treating triple-class-exposed patients.
Findings suggest broader use of outpatient protocols for teclistamab with prophylactic strategies may improve patient experience.

Cite This Study

Lund et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4d0 https://doi.org/10.1182/blood-2025-718

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows prophylactic tocilizumab reduces cytokine release syndrome in relapsed/refractory multiple myeloma, indicating a safer approach.

Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider